Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has significantly expanded its capabilities to generate large collections of distinct, unique bispecific antibodies against target combinations by contracting R&D services to FairJourney Biologics.
Under an agreement signed with Merus, FairJourney Biologics will provide R&D services to strengthen Merus R&D resources for selecting the most promising common light chain antibodies generated by the MeMo® transgenic mouse.
In the press release Merus stated that FairJourney Biologics was founded by a group of scientists that have a significant track record in generating therapeutic antibodies to industry standards. “They have consistently impressed us with their speed and expertise,” added Mark Throsby, COO at Merus B.V.